Chapter from the book *Liver Transplantation - Basic Issues*
Downloaded from: http://www.intechopen.com/books/liver-transplantation-basic-issues

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
The Post-Reperfusion Syndrome (PRS): Diagnosis, Incidence and Management

Kyota Fukazawa and Ernesto A. Pretto, Jr.
University of Miami, Miller School of Medicine, Miami, Florida USA

1. Introduction

Despite the remarkable advances in the peri-operative management of the liver transplant recipient, the post-reperfusion syndrome (PRS) continues to be an important intra-operative risk factor for impaired graft function, and morbidity and mortality of the recipient. In order to institute preventive measures several studies have attempted to elucidate risk factors for PRS. Those identified risk factors and proposed mechanisms underlying the development of PRS, as well as current issues with PRS will be discussed in the following three sections.

2. Diagnosis

The post-reperfusion syndrome (PRS) which occurs during liver transplantation was first diagnosed by Aggarwal et al in 1987 and described as cardiovascular collapse following revascularization of the liver graft. They defined PRS as severe hemodynamic instability, persistent hypotension (a greater than 30% drop below the anhepatic mean arterial blood pressure (MAP) within 5 minutes of reperfusion and sustained for at least 1 minute), accompanied by asystole, or significant arrhythmias as well as development of significant, fibrinolysis requiring treatment. Up until now this definition remains the same with some modifications. Hilmi et al defined mild PRS as a drop in MAP to less than 30% of mean baseline MAP observed during the anhepatic stage associated with bradycardia and sustained for less than 5 minutes, and requiring calcium or epinephrine boluses, but without the need for continuous vasopressor infusion. Severe PRS was defined as persistent severe hypotension with a greater than 30% reduction in MAP from mean baseline MAP during the anhepatic stage, associated with asystole, significant arrhythmias, and requiring prolonged vasopressor infusion (until end of surgery) and fibrinolysis. Other reports have used only persistent hypotension as the defining endpoint for PRS. Therefore, inconsistency of definitions makes it difficult to draw conclusions concerning the precise incidence of PRS, its clinical presentation and causes.

These definitions rely on the value of the percent change in MAP from the mean baseline MAP observed during the anhepatic stage. It so happens that the anhepatic stage is fraught with hemodynamic fluctuations related to manipulation of the inferior vena cava (IVC), blood loss, veno-venous bypass, hypothermia, metabolic acidosis, etc., which are common during the an-hepatic phase. These multi-factorial hemodynamic perturbations call into
Severe hemodynamic instability
Persistent hypotension
Greater than 30% of the anhepatic MAP within 5
minutes sustained for at least 1 minute
Asystole
Significant arrhythmias
Development of significant fibrinolysis

Table 1. Definition of Post-Reperfusion Syndrome (PRS)

Abbreviations: MAP: Mean Arterial Blood Pressure

question the reliability and accuracy of PRS incidence and severity based on one parameter
namely, % change in MAP. Moreover, pre-treatment with bolus doses of vasopressors,
including calcium chloride, vasopressin or methylene blue immediately prior to reperfusion
of the portal vein, intended to preempt severe hypotension post-reperfusion also introduce
ers into the calculation of % changes in MAP, before and after reperfusion. More
importantly, in some instances there may be a complete absence of hemodynamic instability
even in the presence of severe graft dysfunction following reperfusion when portal vein
flow is inadequate. This is called the no-reflow phenomenon. No-reflow is associated with
high vascular resistance in the microcirculation of the graft secondary to multiple factors,
such as: tissue edema, leukocyte plugging and the accumulation of pro-inflammatory factors
and cellular debris; vasoconstriction of the tissues due to cold preservation, portal vein
thrombosis, or presence of large collateral veins (porto-systemic shunts). In those cases,
there is a gradual resolution of no-reflow and hemodynamic fluctuations may be delayed
beyond the immediate portal vein or even hepatic artery reperfusion periods when the
organ is better perfused. For these reasons, PRS incidence may not be accurately ascertained
when a narrow window of MAP readings is used in its determination. Likewise, major
changes in MAP in the immediate post-reperfusion period may or may not be associated
with graft quality. Although cardiovascular collapse following reperfusion is common in
liver transplant practice, it is essential to elucidate the underlying mechanisms of PRS, and
to determine more accurately the relationship between PRS and graft quality. Is PRS a cause
of poor graft quality or is it a consequence? The definitive answer to this question can only
be found in the conduct of a blinded controlled prospective study with well-defined end
points in a large cohort of patients. The results of such a study would help to broaden the
scope of what constitutes the diagnosis of PRS.

3. Incidence of PRS and confounding factors

To date, there is wide variation in the reported incidence of PRS (5.9-61.3%). There are
several factors attributable to these wide variations, among these are: differences in surgical
technique, intraoperative hemodynamic management, as well as chronological and
geographical factors. Piggyback technique is used for implantation of the liver graft without
interrupting IVC flow. It was first introduced into human liver transplantation in the late
1980’s. Veno-venous bypass (VVB) was also introduced in the 1980’s. Those techniques were
developed to enable more stable hemodynamics upon manipulation of the IVC during
orthotopic liver transplantation. Because volume status of the recipient before reperfusion
can be an important risk factor for PRS, more stable hemodynamics before reperfusion may
decrease its incidence, although the impact of surgical technique between conventional or

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>N</th>
<th>Country</th>
<th>Type of Study</th>
<th>Incidence of PRS</th>
<th>Identified Risk Factors for PRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryu HG et. al.</td>
<td>2011</td>
<td>62</td>
<td>Korea</td>
<td>Blind Controlled Prospective Study</td>
<td>-</td>
<td>Vasodilator release form graft (Kallikrein-Kinin)</td>
</tr>
<tr>
<td>Garcia-Gil FA et al.</td>
<td>2011</td>
<td>153</td>
<td>Spain</td>
<td>Blind Controlled Prospective Study</td>
<td>-</td>
<td>Type of Preservation Solution</td>
</tr>
<tr>
<td>Bukowicka B et al.</td>
<td>2011</td>
<td>340</td>
<td>Poland</td>
<td>Retrospective Chart Review</td>
<td>12.1%</td>
<td>Cold Ischemia Time, Transplant Technique*, Operating Time, Transfusion Requirements due to Donor-Recipient Size Mismatch, Age</td>
</tr>
<tr>
<td>Fukazawa K et al.</td>
<td>2011</td>
<td>715</td>
<td>USA</td>
<td>Retrospective Chart Review</td>
<td>55.7%</td>
<td>-</td>
</tr>
<tr>
<td>Siniscalchi A et al.</td>
<td>2010</td>
<td>58</td>
<td>Italy</td>
<td>Retrospective Chart Review</td>
<td>41.0%</td>
<td>MELD, Preoperative Creatinine</td>
</tr>
<tr>
<td>Paugam-Burtz et al.</td>
<td>2009</td>
<td>75</td>
<td>France</td>
<td>Prospective Study</td>
<td>25.0%</td>
<td>PortoCaval Shunt, Cold Ischemia Time</td>
</tr>
<tr>
<td>Hilm I et al.</td>
<td>2008</td>
<td>338</td>
<td>USA</td>
<td>Retrospective Chart Review</td>
<td>55.0%</td>
<td>Recipient Age</td>
</tr>
<tr>
<td>Ko JS et. al.</td>
<td>2008</td>
<td>87</td>
<td>Korea</td>
<td>Retrospective Chart Review</td>
<td>28.6% (UW) 61.3% (HTK)</td>
<td>Type of Preservation Solution</td>
</tr>
<tr>
<td>Homvises B et. al.</td>
<td>2008</td>
<td>20</td>
<td>Thailand</td>
<td>Retrospective Chart Review</td>
<td>-</td>
<td>Volume of Flush Before Reperfusion</td>
</tr>
<tr>
<td>Pertejo MA et. al.</td>
<td>2007</td>
<td>551</td>
<td>Spain</td>
<td>Retrospective Chart Review</td>
<td>16-27%</td>
<td>-</td>
</tr>
</tbody>
</table>
### Table 2 (continued) Reported Incidence of PRS

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Country</th>
<th>Study Design</th>
<th>Transplant technique</th>
<th>Response to IVC clamp</th>
<th>Preemptive Phenylephrine Treatment</th>
<th>Cold Ischemia Time</th>
<th>Long Anhepatic Period</th>
<th>Higher Calcium Requirement</th>
<th>Lower CVP</th>
<th>Veno-venous bypass</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moreno et al.</td>
<td>2005</td>
<td>Spain</td>
<td>Prospective Study</td>
<td>Retrograde</td>
<td>42.5% (PVR)</td>
<td>29.0% (Preemptive)</td>
<td>36%</td>
<td>22% (Without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Garatu et al.</td>
<td>1997</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>30%</td>
<td>54%</td>
<td>20%</td>
<td>25% (without VVB)</td>
<td>28%</td>
<td>15%</td>
<td>No difference</td>
</tr>
<tr>
<td>Ayanoglu et al.</td>
<td>2003</td>
<td>Turkey</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>48.9%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Chui et al.</td>
<td>2000</td>
<td>Australia</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>12.8%</td>
<td>48%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
<tr>
<td>Acosta et al.</td>
<td>1999</td>
<td>Spain</td>
<td>Retrospective Chart</td>
<td>Conventional ICV</td>
<td>29.0%</td>
<td>44%</td>
<td>20%</td>
<td>30% (without VVB)</td>
<td>30%</td>
<td>10%</td>
<td>No difference</td>
</tr>
</tbody>
</table>

**Abbreviations:**

- CVP: Central venous pressure
- HTK: Histidine-triptophan-ketoglutarate solution
- IVC: Inferior vena cava
- ICU: Intensive care unit
- IVC clamp: Inferior vena cava clamp
- MELD: Models for End-Stage Liver Disease
- UW: University of Wisconsin solution
- VVB: Veno-venous bypass

**Note:**

- (No difference between with and without VVB)
piggy-back techniques on PRS is still in debate. In addition, VVB reduces small bowel edema, which has been suggested as a primary site for the production and release of potent vasoactive inflammatory mediators. With the improvement of transplant outcomes and recognition of risk factors for graft survival, expanded criteria donors (ECD) have been more frequently used due to severe shortages of organ donors. More frequent usage of ECD as well as the introduction of new surgical techniques may affect the incidence of PRS, depending on the era, a chronological factor. Also, geographical areas with low organ donor conversion rates and acute shortage of organs for transplantation will invariably result in higher usage rates of ECD, as well as sicker recipients due to longer waiting times. Therefore, the incidence of PRS will vary with geographical area. The interpretation of those results also needs to take chronological and geographical factors into account as confounding factors.

4. Risk factors for PRS

Well-established risk factors and recognized mechanisms associated with PRS include: i) volume status of the recipient before reperfusion, ii) myocardial depression due to embolization of cold preservation solution into the systemic circulation, and iii) release of vasoactive pro-inflammatory factors originating in activated Kupffer cells of the post-ischemic liver graft.

4.1 Pre-reperfusion volume status

The liver is an important reservoir of blood, containing a total of about 250-500ml or 18-30ml/100g of blood. In liver transplantation, the donor liver graft will be rapidly filled with recipient blood following revascularization of the portal vein, resulting in immediate volume shifts and occasionally, hypotension. De La Morena et al. determined that an insufficient increase in preload is a main causative factor of PRS (or reperfusion hypotension) in an observational study using transesophageal echocardiography (TEE). Maintaining a high cardiac output is essential to ensure adequate perfusion of organs in liver transplantation. However, high cardiac output can be accomplished by maintaining preload, which may be difficult given that the operation itself is associated with major changes in volume and afterload, in addition to blood loss, third space losses, and ongoing ascites production. This result will support the hypothesis that volume shift is one of the main components of reperfusion hypotension and maintaining adequate preload before reperfusion is crucial. Also, size mismatch between donor and recipient can cause additional volume shifts, as evidenced by the fact that a large-for-size donor relative to recipient body size causes more severe reperfusion hypotension. The BSA index (BSAi) may help to more accurately match donor and recipient organs in whole organ liver transplantation.

4.2 Myocardial performance

In addition to volume shifts, a change in myocardial performance is another component of reperfusion hypotension/PRS. Myocardial performance is reduced by a decrease in temperature, acid-base and electrolyte disturbances, which are all caused by the flushing of residual preservation solution into the systemic circulation after revascularization of the graft. Acidosis following reperfusion due to release of acidic fluid from ischemic bowel and liver graft is a common finding in liver transplantation. Acute acidosis can cause
tachycardia, dysrythmias, and severe myocardial depression by producing changes in resting membrane potential and threshold potential and an increase in the rate of phase IV depolarization. Therefore the use of VVB has been proposed to decrease the incidence of PRS by minimizing small bowel edema/ischemia with varying results.

4.3 Donor factors

Lastly, the release of inflammatory factors from the post-ischemic donor liver graft into the recipient systemic circulation also can trigger a systemic inflammatory chain reaction that can lead to systemic hypotension and multi-organ dysfunction. Therefore, the quality of the donor can be a risk factor for PRS, and postoperative graft function (primary non-function, and graft survival). A donor organ with certain characteristics such as extreme age, adverse past medical history, preexisting liver damage or disease, obesity, hemodynamic instabilities, deceased cardiac donor (DCD), risk of sepsis and malignancies, hypernatremia, and prolonged ICU stay, may be more susceptible to ischemia, and more likely to have higher incidence of primary non-function (PNF), delayed function or subsequent risk for reduction in long-term graft survival. Similarly, several studies have attempted to identify donor risk factors for PRS. Hilmi et al reported warm ischemia time as a risk factor and more recently Paugam-Burtz, et al reported cold ischemia time is also a risk for PRS. In addition to those prior studies, donor age is an important risk factor for PRS. The older donor graft has a lower tolerance for hypoxia, and a greater susceptibility to reperfusion injury, probably due to metabolic changes associated with senescence, age related atherosclerotic changes in vascular structures, or steatotic changes of the parenchyma. The type of preservation solution and the graft flushing techniques have also been shown to affect the severity of PRS.

5. Strategy for the intraoperative management of PRS

Warm recipient blood flows into the cold organ after revascularization of the portal vein, causing immediate volume shifts, re-oxygenation of the ischemic organ, and outflow of cold preservation solution saturated with vasoactive pro-inflammatory factors. Optimization of volume status in the recipient prior to reperfusion may minimize hemodynamic changes related to volume shifts by maximizing hemodynamic capacity to maintain good perfusion pressure throughout the liver graft, especially the large-for-size graft. TEE coupled with close monitoring of hemodynamic parameters with continuous cardiac output (CO)/SvO2, and standard cardiac monitors are particularly helpful to ensure hemodynamic integrity of the recipient. To obtain sufficient perfusion of the liver graft, especially through the hepatic microcirculation, vasodilating agents such as prostaglandin or calcium channel blockers can be used but with caution since those agents can aggravate hemodynamic instability. To minimize the sudden outflow of preservation solution from the liver graft, flushing the organ prior to reperfusion has been used and currently proposed as the most effective way of preventing hemodynamic instability associated with the inadvertent release of preservation solution. Ingredients of the flush solution as well as rate of infusion, temperature of flush solution, and amount of solution are still under investigation. Gradual and homogeneous perfusion of the organ by machine perfusion immediately prior to implantation may improve graft function by effectively removing the pro-inflammatory factors from the graft microcirculation, may reduce PRS and improve short and long term graft survival, especially in the ECD. Preemptive use of vasopressors may help maintain the
systemic blood pressure but may not improve the % change in blood pressure or graft outcome. Preemptive use of oxidative free radical scavenging agents or attempts at counteracting vasoactive inflammatory factors is another area of research. For example, methylene blue has been used to scavenge nitric oxide related vasodilation in various shock states. Also, several oxidative free radical scavengers, vasodilators (inhaled nitric oxide, prostaglandin E), and Ibuprofen (cyclooxygenase inhibitor) have been studied as a way to suppress the pro-inflammatory cascade post-reperfusion. The benefits of these treatment strategies on PRS and postoperative graft function are inconclusive, and larger clinical trials are needed. This will require a consortium of leading academic liver transplant centers to conduct multicenter clinical trials. To minimize the impairment of cardiac performance following reperfusion, electrolyte abnormalities, especially hypocalcemia and hyperkalemia need to be corrected prior to reperfusion. Magnesium replacement may need to be considered, especially when there is hypocalcemia due to intraoperative transfusion and citrate intoxication. Citrate binds magnesium as well as calcium, causing acute hypomagnesemia.

6. Conclusions

After having contributed to the establishment of liver transplantation as a safe and definitive treatment option for patients with end stage liver disease, including those with ESLD complicated by hepatocarcinomas, in the latter half of the 20th century, the next challenge to Transplant Anesthesiologists and Critical Care Specialists in the 21st is to continue to improve the perioperative management of the donor and organ transplant recipient during the most critical period of the liver transplant procedure namely, revascularization, reperfusion and re-oxygenation of the graft. This effort will undoubtedly require multicenter research collaborations, the determination of better and more reliable end-points for PRS and graft function, and the institution and conduct of multicenter clinical trials. Inevitably research will most likely reveal the need for a multi-factorial treatment strategy to preempt or mitigate PRS and the deterioration of graft function, especially of the ECD graft. This effort comprises preconditioning of the donor, preservation and post condition of the recipient transplanted, a process that can be succinctly described as ‘organ resuscitation’. Better post-transplant outcomes will decrease the costs involved in re-transplantation, and prolonged ICU and hospital stays.

7. References


The Post-Reperfusion Syndrome (PRS): Diagnosis, Incidence and Management


during machine perfusion on preservation quality of marginal donor livers. 
*Cryobiology*, 60, 3, (Jun,2010), pp. 337-343,1090-2392 (Electronic) 0011-2240 (Linking)


This book covers a wide spectrum of topics including history of liver transplantation, ischemia-reperfusion injury, immunology of liver transplantation, viral hepatitis and liver transplantation, other indications for liver transplantation, prognostic factors and perioperative period. The authors of the chapters are experts in their respective fields. They are proponents covering different aspects of liver transplantation and come from many centers across the world. The interdisciplinary approach and the authority of the contributors resulted in a valuable reference to anyone interested in developing a global view in liver transplantation including medical students, residents, fellows, nurses, and practicing physicians and surgeons as well as researchers in the field of liver transplantation.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: